Toviaz fesoterodine: Phase IV data

A double-blind, placebo-controlled, international Phase IV trial in 642 patients with OAB who had a suboptimal response to Detrol LA tolterodine ER showed that once-daily Toviaz significantly reduced the number of urge urinary incontinence episodes per 24 hours, the primary endpoint, by 2.37 episodes compared to baseline at week 12 (p<0.0001). The trial enrolled patients to initially receive open-label, once-daily Detrol LA for 2 weeks. Patients with a suboptimal response to Detrol LA, defined as a <50% reduction in mean urge urinary incontinence per 24 hours from baseline after 2 weeks, were randomized to receive placebo or once-daily 4 mg Toviaz for 1 week followed by once-daily 8 mg Toviaz for 11 additional weeks. ...